Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model

Blood

Volumn 101, Issue 2, 2003, Pages 594-601

  Jordan, Michael B ^a,b   Van Rooijen, Nico ^a,b   Izui, Shozo ^a,b   Kappler, John ^a,b   Marrack, Philippa ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CLODRONIC ACID; CORTICOSTEROID; ERYTHROCYTE ANTIBODY; IMMUNOGLOBULIN G; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CELL DESTRUCTION; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ENCAPSULATION; ERYTHROCYTE; ERYTHROPHAGOCYTOSIS; FEMALE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENECTOMY;

EID: 0037438379     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0061     Document Type: Article

References (47)

1. Ware R, Rosse W. Autoimmune hemolytic anemia. In: Nathan DG, Orkin SH, eds. Nathan and Oski's Hematology of Infancy and Childhood. Vol 1. 5th ed. Philadelphia, PA: WB Saunders; 1998:499-522.
2. Schreiber AD. Systemic lupus erythematosus: hematological aspects. J Rheumatol. 1980;7:395-397.
3. NIH conference: pathophysiology of immune hemolytic anemia. Ann Intern Med. 1977;87:210-222.
4. Axelson JA, LoBuglio AF. Immune hemolytic anemia. Med Clin North Am. 1980;64:597-606.
5. Saif MW. HIV-associated autoimmune hemolytic anemia: an update. AIDS Patient Care STDS. 2001;15:217-224.
6. Izui S, Berney T, Shibata T, Fulpius T, Fossati L, Merino R. Molecular and cellular basis for pathogenicity of autoantibodies. Tohoku J Exp Med. 1994;173:15-30.
7. Fossati-Jimack L, Ioan-Facsinay A, Reininger L, et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med. 2000;191:1293-1302.
8. Fossati-Jimack L, Reininger L, Chicheportiche Y, et al. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med. 1999;190:1689-1696.
9. Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med. 2002;195:665-672.
10. Hazenbos WL, Gessner JE, Hofhuis FM, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity. 1996;5:181-188.
11. Hazenbos WL, Heijnen IA, Meyer D, et al. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol. 1998;161:3026-3032.
12. Meyer D, Schiller C, Westermann J, et al. FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood. 1998;92:3997-4002.
13. Schiller C, Janssen-Graalfs I, Baumann U, et al. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol. 2000;30:481-490.
14. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21-26.
15. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998;38:375-388.
16. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(suppl 2):S66-S80.
17. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate: an enzyme-histochemical study. Cell Tissue Res. 1984;238:355-358.
18. Claassen I, Van Rooijen N, Claassen E. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage 'suicide' technique. J Immunol Methods. 1990;134:153-161.
19. van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods. 1996;193:93-99.
20. Naito M, Nagai H, Kawano S, et al. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol. 1996;60:337-344.
21. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989;45:97-104.
22. van Rooijen N, Sanders A. Elimination, blocking, and activation of macrophages: three of a kind? J Leukoc Biol. 1997;62:702-709.
23. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93.
24. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, Isturiz MA. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood. 2000;96:2834-2840.
25. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109:280-287.
26. Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice, IV: identification and distribution in mouse spleen. J Exp Med. 1975;141:804-820.
27. Steinman RM, Kaplan G, Witmer MD, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice, V: purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J Exp Med. 1979;149:1-16.
28. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med. 1990;172:1025-1033.
29. Richards PJ, Williams BD, Williams AS. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology (Oxford). 2001;40:978-987.
30. Sokol RJ, Hewitt S, Stamps BK, Hitchen PA. Autoimmune haemolysis in childhood and adolescence. Acta Haematol. 1984;72:245-257.
31. Carapella de Luca E, Casadei AM, di Piero G, Midulla M, Bisdomini C, Purpura M. Auto-immune haemolytic anaemia in childhood: follow-up in 29 cases. Vox Sang. 1979;36:13-20.
32. Buchanan GR, Boxer LA, Nathan DG. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr. 1976;88:780-783.
33. Heisel MA, Ortega JA. Factors influencing prognosis in childhood autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol. 1983;5:147-152.
34. Bell WR Jr. Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37:22-25.
35. Hansen K, Singer DB. Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. Pediatr Dev Pathol. 2001;4:105-121.
36. Katkhouda N, Hurwitz MB, Rivera RT, et al. Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Ann Surg. 1998;228:568-578.
37. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61:98-102.
38. Kooguchi K, Hashimoto S, Kobayashi A, et al. Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect Immun. 1998;66:3164-3169.
39. Leemans JC, Juffermans NP, Florquin S, et al. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol. 2001;166:4604-4611.
40. Nieuwenhuljzen GA, Haskel Y, Lu Q, et al. Macrophage elimination increases bacterial translocation and gut-origin septicemia but attenuates symptoms and mortality rate in a model of systemic inflammation. Ann Surg. 1993;218:791-799.
41. Savoy AC, Lupan DM, Manalo PB, et al. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun. 1997;65:1800-1807.
42. Wijburg OL, Simmons CP, van Rooijen N, Strugnell RA. Dual role for macrophages in vivo in pathogenesis and control of murine Salmonella enterica var. Typhimurium infections. Eur J Immunol. 2000;30:944-953.
43. Ebe Y, Hasegawa G, Takatsuka H, et al. The role of Kupffer cells and regulation of neutrophil migration into the liver by macrophage inflammatory protein-2 in primary listerlosis in mice. Pathol Int. 1999;49:519-532.
44. Emmanuilidis K, Weighardt H, Maier S, et al. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol. 2001;167:3919-3927.
45. Hamano S, Yoshida H, Takimoto H, et al. Role of macrophages in acute murine cytomegalovirus infection. Microbiol Immunol. 1998;42:607-616.
46. Pinto AJ, Stewart D, van Rooijen N, Morahan PS. Selective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene diphosphonate: effects on antimicrobial resistance. J Leukoc Biol. 1991;49:579-586.
47. Qian Q, Jutila MA, Van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol. 1994;152:5000-5008.